BMS reaches free licensing deal for Reyataz in developing world

Share this article:
Bristol-Myers Squibb (BMS) is reported to have reached a deal to license its AIDS drug Reyataz to two generic drug manufacturers in the developing world free of charge, one of the first such agreements involving a second-line AIDS treatment. Under the deal to be announced today, BMS will grant a royalty-free license to South Africa’s Aspen PharmaCare Holdings and India’s Emcure Pharmaceuticals to make and sell atazanavir, the molecule Reyataz is based on, in sub-Saharan Africa, The Wall Street Journal reported. Reyataz is a relatively new AIDS drug considered especially effective when used in a “cocktail” combination with Abbott Laboratories’ Norvir. BMS received US marketing approval for Reyataz in 2003. The drug’s patent runs out in 2017.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.